The application of genome-wide 5-hydroxymethylcytosine studies in cancer research

Epigenomics

Volumn 9, Issue 1, 2017, Pages 77-91

  Thomson, John P ^a   Meehan, Richard R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

5hmC; biomarker; cancer; epigenetics; genome wide sequencing; hydroxymethylation

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CARCINOGEN; 5 METHYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; TUMOR MARKER;

CANCER RESEARCH; CANCER THERAPY; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DNA SEQUENCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM; PROCEDURES;

5-METHYLCYTOSINE; ANIMALS; BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 85009078232     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi-2016-0122     Document Type: Review

References (97)

1. Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17(5), 284-299 (2016)
2. Liu F, Wang L, Perna F, Nimer SD. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat. Rev. Cancer 16(6), 359-372 (2016)
3. Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol. Cell 55(6), 904-915 (2014)
4. Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife 3, e02313 (2014)
5. Shah MA, Denton EL, Arrowsmith CH, Lupien M, Schapira M. A global assessment of cancer genomic alterations in epigenetic mechanisms. Epigenetics Chromatin 7(1), 29 (2014)
6. Yang Z, Jones A, Widschwendter M, Teschendorff AE. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol. 16, 140 (2015)
7. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279), 360-363 (2010)
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011)
9. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13(7), 497-510 (2013)
10. Sproul D, Meehan RR. Genomic insights into cancerassociated aberrant CpG island hypermethylation. Brief Funct. Genomics 12(3), 174-190 (2013)
11. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011)
12. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002)
13. Dunican DS, Cruickshanks HA, Suzuki M et al. Lsh regulates LTR retrotransposon repression independently of Dnmt3b function. Genome Biol. 14(12), R146 (2013)
14. Hackett JA, Reddington JP, Nestor CE et al. Promoter DNA methylation couples genome-defence mechanisms to epigenetic reprogramming in the mouse germline. Development 139(19), 3623-3632 (2012)
15. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009)
16. Thomson JP, Hunter JM, Meehan RR. Deep C diving: mapping the low-abundance modifications of the DNA demethylation pathway. Genome Biol. 14(5), 118 (2013)
17. Bachman M, Uribe-Lewis S, Yang X, Williams M, Murrell A, Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat. Chem. 6(12), 1049-1055 (2014)
18. He YF, Li BZ, Li Z et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333(6047), 1303-1307 (2011)
19. Xu X, Watt DS, Liu C. Multifaceted roles for thymine DNA glycosylase in embryonic development and human carcinogenesis. Acta Biochim. Biophys. Sin. 48(1), 82-89 (2016)
20. Guo F, Li X, Liang D et al. Active and passive demethylation of male and female pronuclear DNA in the mammalian zygote. Cell Stem Cell 15(4), 447-458 (2014)
21. Xu G-L, Wong J. Oxidative DNA demethylation mediated by Tet enzymes. Natl Sci. Rev.2, 318-328 (2015)
22. Goodwin S, Mcpherson JD, Mccombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17(6), 333-351 (2016)
23. Nik-Zainal S, Davies H, Staaf J et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534(7605), 47-54 (2016)
24. Gu L, Frommel SC, Oakes CC et al. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nat. Genet. 47(1), 22-30 (2015)
25. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324(5929), 929-930 (2009)
26. Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: cause or consequence Genomics104(5), 352-357 (2014)
27. Neri F, Dettori D, Incarnato D et al. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 34(32), 4168-4176 (2015).
28. Ichimura N, Shinjo K, An B et al. Aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev. Res. (Phila.) 8(8), 702-711 (2015)
29. Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 9(5), 1827-1840 (2014)
30. Thienpont B, Steinbacher J, Zhao H et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537(7618), 63-68 (2016).
31. Laird A, Thomson JP, Harrison DJ, Meehan RR. 5-hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics 5(6), 655-669 (2013)
32. Shen L, Wu H, Diep D et al. Genome-wide analysis reveals TET-and TDG-dependent 5-methylcytosine oxidation dynamics. Cell 153(3), 692-706 (2013)
33. Nestor CE, Ottaviano R, Reddington J et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 22(3), 467-477 (2012)
34. Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat. Biotechnol. 30(11), 1107-1116 (2012)
35. Thomson JP, Hunter JM, Nestor CE et al. Comparative analysis of affinity-based 5-hydroxymethylation enrichment techniques. Nucleic Acids Res. 41(22), e206 (2013)
36. Bogdanovic O, Smits AH, De La Calle Mustienes E et al. Active DNA demethylation at enhancers during the vertebrate phylotypic period. Nat. Genet. 48(4), 417-426 (2016)
37. Li X, Liu Y, Salz T, Hansen KD, Feinberg AP. Whole genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver. Genome Res. 26, 1730-1741 (2016)
38. Nestor CE, Lentini A, Hägg-Nilsson C et al. 5-hydroxymethylcytosine remodeling precedes lineage specification during differentiation of human CD4+ T-cells. Cell Reports 16(2), 559-570 (2016)
39. Neri F, Incarnato D, Krepelova A et al. Single-base resolution analysis of 5-formyl and 5-carboxyl cytosine reveals promoter DNA methylation dynamics. Cell Rep. 10, 674-683 (2015)
40. Sproul D, Kitchen RR, Nestor CE et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol. 13(10), R84 (2012).
41. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006)
42. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011)
43. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009)
44. Bell RE, Golan T, Sheinboim D et al. Enhancer methylation dynamics contribute to cancer plasticity and patient mortality. Genome Res. 26(5), 601-611 (2016)
45. Gao F, Xia Y, Wang J et al. Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma. Genome Biol. 15(12), 533 (2014)
46. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6), 553-567 (2010)
47. Rampal R, Alkalin A, Madzo J et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 9(5), 1841-1855 (2014)
48. Thomson JP, Ottaviano R, Unterberger EB et al. Loss of Tet1-associated 5-hydroxymethylcytosine is concomitant with aberrant promoter hypermethylation in liver cancer. Cancer Res. 76(10), 3097-3108 (2016).
49. Gambichler T, Sand M, Skrygan M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res. 23(3), 218-220 (2013)
50. Jin SG, Jiang Y, Qiu R et al. 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 71(24), 7360-7365 (2011)
51. Kudo Y, Tateishi K, Yamamoto K et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103(4), 670-676 (2012)
52. Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS ONE 7(7), e41036 (2012)
53. Liu C, Liu L, Chen X et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS ONE 8(5), e62828 (2013)
54. Park JL, Kim HJ, Seo EH et al. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3-shore. Oncotarget 6(35), 37647-37662 (2015)
55. Chen K, Zhang J, Guo Z et al. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 26(1), 103-118 (2015)
56. Kroeze LI, Aslanyan MG, Van Rooij A et al. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood 124(7), 1110-1118 (2014)
57. Lian CG, Xu Y, Ceol C et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150(6), 1135-1146 (2012).
58. Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 30(7), 733-750 (2016)
59. Dawlaty MM, Ganz K, Powell BE et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 9(2), 166-175 (2011)
60. Putiri EL, Tiedemann RL, Thompson JJ et al. Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. Genome Biol. 15(6), R81 (2014).
61. Ye C, Tao R, Cao Q et al. Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma. Int. J. Oncol. 49(2), 589-602 (2016)
62. Hon GC, Song CX, Du T et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell 56(2), 286-297 (2014)
63. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 62(14), 4075-4080 (2002)
64. Forloni M, Gupta R, Nagarajan A et al. Oncogenic EGFR represses the TET1 DNA demethylase to induce silencing of tumor suppressors in cancer cells. Cell Rep. 16(2), 457-471 (2016)
65. Li L, Li C, Mao H et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep. 6, 26591 (2016)
66. Pei YF, Tao R, Li JF et al. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and reexpression. Oncotarget 7(21), 31322-31335 (2016)
67. Kroeze LI, Van Der Reijden BA, Jansen JH. 5-hydroxymethylcytosine: an epigenetic mark frequently deregulated in cancer. Biochim. Biophys. Acta 1855(2), 144-154 (2015)
68. Pei YF, Lei Y, Liu XQ. MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1. Biochim. Biophys. Acta 11(10), 16 (2016)
69. Wu MZ, Chen SF, Nieh S et al. Hypoxia drives breast tumor malignancy through a TET-TNFalpha-p38-MAPK signaling axis. Cancer Res. 75(18), 3912-3924 (2015)
70. Sang Y, Cheng C, Tang XF, Zhang MF, Lv XB. Hypermethylation of TET1 promoter is a new diagnosic marker for breast cancer metastasis. Asian Pac. J. Cancer Prev. 16(3), 1197-1200 (2015)
71. Letouze E, Martinelli C, Loriot C et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23(6), 739-752 (2013)
72. Oermann EK, Wu J, Guan KL, Xiong Y. Alterations of metabolic genes and metabolites in cancer. Semin. Cell Dev. Biol. 23(4), 370-380 (2012)
73. Toro JR, Nickerson ML, Wei MH et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73(1), 95-106 (2003)
74. Yin R, Mao SQ, Zhao B et al. Ascorbic acid enhances Tetmediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135(28), 10396-10403 (2013)
75. Nestor CE, Ottaviano R, Reinhardt D et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol. 16(1), 11 (2015)
76. Baylin SB, Hoppener JW, De Bustros A, Steenbergh PH, Lips CJ, Nelkin BD. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res. 46(6), 2917-2922 (1986)
77. Cimmino L, Dawlaty MM, Ndiaye-Lobry D et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16(6), 653-662 (2015)
78. Struhl K. Is DNA methylation of tumour suppressor genes epigenetic Elife 3, e02475 (2014)
79. Gu J, Stevens M, Xing X et al. Mapping of variable DNA methylation across multiple cell types defines a dynamic regulatory landscape of the human genome. G3 (Bethesda) 6(4), 973-986 (2016)
80. Chiappinelli KB, Strissel PL, Desrichard A et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5), 974-986 (2015)
81. Roulois D, Loo Yau H, Singhania R et al. DNAdemethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5), 961-973 (2015)
82. Booth MJ, Ost TW, Beraldi D et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat. Protoc. 8(10), 1841-1851 (2013)
83. Yu M, Hon GC, Szulwach KE et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 149(6), 1368-1380 (2012)
84. Thomson JP, Moggs JG, Wolf CR, Meehan RR. Epigenetic profiles as defined signatures of xenobiotic exposure. Mutat. Res. 764-765, 3-9 (2014)
85. Thomson JP, Hunter JM, Lempiainen H et al. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res. 41(11), 5639-5654 (2013)
86. Thomson JP, Lempiainen H, Hackett JA et al. Nongenotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biol. 13(10), R93 (2012).
87. Lian CG, Xu S, Guo W et al. Decrease of 5-hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid. Mol. Carcinog. 54(11), 1503-1507 (2014)
88. Gurbuz I, Chiquet-Ehrismann R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): a focus on its role in cancer. Int. J. Biochem. Cell. Biol. 62, 142-146 (2015)
89. Lempiainen H, Couttet P, Bolognani F et al. Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicol. Sci. 131(2), 375-386 (2013)
90. Gustafson CB, Yang C, Dickson KM et al. Epigenetic reprogramming of melanoma cells by vitamin C treatment. Clin. Epigenetics 7(1), 51 (2015)
91. Strand SH, Hoyer S, Lynnerup AS et al. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clin. Epigenetics 7, 111 (2015)
92. Zhang F, Liu Y, Zhang Z et al. 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci. Rep. 6, 20882 (2016)
93. Yang Q, Wu K, Ji M et al. Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J. Biomed. Nanotechnol. 9(9), 1607-1616 (2013)
94. Sproul D, Nestor C, Culley J et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc. Natl Acad. Sci. USA 108(11), 4364-4369 (2011)
95. Moarii M, Reyal F, Vert JP. Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype. Hum. Genomics 9, 26 (2015)
96. Gustafsson M et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med. 6, 82 (2014)
97. Amabile A, Migliara A, Capasso P et al. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell 167(1), 219-232 (2016).